Background The proportion of patients infected with SARS-CoV-2 that are prescribed
antibiotics is uncertain, and may contribute to patient harm and global antibiotic resistance …

The presence of SARS-CoV-2 was officially documented in Europe at the end of February
2020. Despite many observations, the real impact of COVID-19 in the European Union (EU) …

Objective To provide guidance on the management of multisystem inflammatory syndrome
in children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan …

Objective To provide guidance on the management of Multisystem Inflammatory Syndrome
in Children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan …

Importance Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …

Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor,
has been proposed to mitigate the cytokine storm syndrome associated with severe COVID …

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May …

Studies have shown that SARS-CoV-2 has the ability to activate and mature proinflammatory
cytokines in the body. Cytokine markers are a group of polypeptide signalling molecules that …

Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …

COVID‐19 is a pandemic disease caused by the new coronavirus SARS‐CoV‐2 that mostly
affects the respiratory system. The consequent inflammation is not able to clear viruses. The …